Nivolumab

The addition of nivolumab to ipilimumab conferred a long-term OS benefit for patients with advanced melanoma, according to study results presented at ESMO Congress.

Immunotherapy before and after surgery significantly improved EFS compared with neoadjuvant immunotherapy only for patients with resectable non-small cell lung cancer, according to a comparison of results from two randomized phase 3 trials.

The addition of nivolumab to low-dose tivozanib did not improve PFS for patients with advanced renal cell carcinoma, according to data from the agent’s manufacturer.

CHICAGO — Individuals with resectable stage III melanoma derived significant EFS benefits with neoadjuvant immunotherapy compared with standard treatment, results from a randomized phase 3 trial presented at ASCO Annual Meeting showed.

CHICAGO — Combination immunotherapy significantly improved outcomes vs. first-line chemotherapy for patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer, according to study results.

CHICAGO — Sequencing encorafenib plus binimetinib with nivolumab and ipilimumab did not delay disease progression in adults with advanced BRAF-mutated melanoma, results from a randomized phase 2 trial showed.

A randomized phase 3 trial that evaluated nivolumab with concurrent chemoradiotherapy for certain patients with advanced lung cancer failed to meet its primary endpoint, according to the agent’s manufacturer.

Healio spoke with Paolo Tarantino, MD, about treatments in the pipeline for metastatic breast cancer.

The addition of nivolumab to ipilimumab significantly improved OS among adults with previously untreated advanced hepatocellular carcinoma, according to a release by the agent’s manufacturer.

In this video, Afsaneh Barzi, MD, PhD, discusses the results of the CheckMate 8HW study.